FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia

The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

Read full article (External website)

1 reply

Trackbacks & Pingbacks

  1. […] FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply